gadolinium dtpa has been researched along with 5-hydroxyindole in 1 studies
| Studies (gadolinium dtpa) | Trials (gadolinium dtpa) | Recent Studies (post-2010) (gadolinium dtpa) | Studies (5-hydroxyindole) | Trials (5-hydroxyindole) | Recent Studies (post-2010) (5-hydroxyindole) |
|---|---|---|---|---|---|
| 12,654 | 664 | 4,051 | 155 | 3 | 33 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Griffiths, JR; Kelland, LR; Kestell, P; Ludwig, C; McIntyre, DJ; McPhail, LD; Robinson, SP | 1 |
1 other study(ies) available for gadolinium dtpa and 5-hydroxyindole
| Article | Year |
|---|---|
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
Topics: Angiogenesis Inhibitors; Animals; Area Under Curve; Biomarkers; Capillary Permeability; Cell Line, Tumor; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium DTPA; Indoles; Magnetic Resonance Imaging; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Pituitary Neoplasms; Prolactinoma; Rats; Rats, Inbred WF; Subcutaneous Tissue; Xanthones | 2006 |